MedTrace Logo

Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

NCT06055764 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2023-09-28

No results posted yet for this study

Summary

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Conditions

  • Metastasis

Interventions

DEVICE

PET/CT

Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room. Procedure: All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital. PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Esraa Mamdouh · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2026-09-30
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055764 on ClinicalTrials.gov